RecruitingNot applicableNCT04509050
Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sonya Heltshe
- Principal Investigator
- Bonnie Ramsey, MDSeattle Children's Hospital
- Intervention
- Ivacaftor or elexacaftor/tezacaftor/ivacaftor(drug)
- Enrollment
- 210 enrolled
- Eligibility
- 10 years · All sexes
- Timeline
- 2020 – 2029
Study locations (20)
- The Children's Hospital Alabama, University of Alabama at Birmingham, Birmingham, Alabama, United States
- Stanford University Medical Center, Palo Alto, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Nemours Children's Clinic, Jacksonville, Florida, United States
- University of Miami, Miami, Florida, United States
- The Nemours Children's Clinic - Orlando, Orlando, Florida, United States
- Riley Hospital for Children, Indianapolis, Indiana, United States
- University of Iowa, Iowa City, Iowa, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- University of Michigan, Michigan Medicine, Ann Arbor, Michigan, United States
- Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
- Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States
- The Minnesota Cystic Fibrosis Center, Minneapolis, Minnesota, United States
- Children's Mercy Kansas City, Kansas City, Missouri, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04509050 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.
- RECRUITINGPHASE1NCT07283770Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNCT07363304Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.Meyer Children's Hospital IRCCS